Introduction:

​

NewPace develops and patented the Implantable Subcutaneous String Defibrillator (ISSD™) which is the first, completely unitary and flexible, rechargeable, lifesaving implanted defibrillator.  Its innovative, minimally invasive, shape introduces a new dimension in subcutaneous cardioverter defibrillators.

 

The ISSD™ is a significantly improved subcutaneous Implantable Cardioverter Defibrillators (ICD) with: easier, less invasive and safer implantation, flexible with no leads within the heart, minimal aesthetic impact, rechargeable, more durable and with secure wireless communication features. It will lead to easier implantation procedures for physicians and significantly improve the lives of Sudden Cardiac Arrest (SCA) patients.

 

End users of the ISSD™ are Electrophysiology (EP) physicians, and patients which are at risk of SCA. Customers are national healthcare systems, hospitals, private heart centers.

 

The overall Phase 2 project objectives include finalizing the development, device validation and getting prepared for first Chronic human trial. The Phase 2 project commenced on 1st July 2018 and will run for 2 years.

 

Newpace has received funding from the European Union’s Horizon 2020 SME Instrument - European R&D Framework Program under grant agreement No 823081